2008-08-04 23:44:03 -

www.frost.com - The Healthcare practice at Frost & Sullivan is pleased to announce its 2008 Quarterly Analyst Briefing Presentation on the North American Pharmaceutical / Biotechnology market to be held on Thursday, August 7, 2008 at 10:00 a.m. PDT.

Pharmaceutical companies increasingly outsource to third parties to save money, speed up processes and get products into the market quicker. It takes an estimated 20 years and $100 million for a drug to reach the market place. Outsourcing allows companies to focus on their core competency areas and expedite the entire process. Functions usually outsourced include manufacturing, clinical trials, packaging and sales force mobilization. Drug discovery outsourcing is the new trend. In Asia pacific, large biopharmaceutical companies outsource to their

local and regional partners. CRO's (Contract Research Organizations) move up the value chain with the desire to serve only few global customers rather than diversify in different areas. Additionally, they are slowly converting into SMO's (Site Management Organizations), where protocol development and monitoring takes place in addition to R&D.

The briefing will focus on factors that encourage pharmaceutical outsourcing, current and future trends, challenges faced by companies and initiatives taken by some of the developing countries to provide a conducive environment for outsourcing. Additionally, the briefing will highlight future prospects and growth opportunities for healthcare industry participants in outsourcing. This briefing will benefit drug and medical device manufacturers, distributors and retailers, research organizations, healthcare outsourcing organizations and health insurance companies who have an interest in accessing the growth potential areas in the pharmaceutical outsourcing industry.

"The pharmaceutical outsourcing trend is expected to continue in the future," states Frost & Sullivan Research Analyst Somya Datta. "All process including manufacturing, R&D and clinical trials will be outsourced in huge volumes. Large pharmaceuticals and biotechnology companies will be the main drivers for this market. The global aging, increasing life expectancy, changing disease epidemology, health awareness and rise in disposable income will support the market growth."

To participate, please email Stephanie Ochoa, Corporate Communications, at stephanie.ochoa@frost.com with the following information: your full name, title, company name, company telephone number, company e-mail address, city, state and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit www.frost.com.

Frost & Sullivan
Stephanie Ochoa, 210-247-2421
Corporate Communications - North America
F: 210-348-1003
stephanie.ochoa@frost.com
www.frost.com